tiprankstipranks
Advertisement
Advertisement
Mirum Shareholders Approve Directors, Auditors and Compensation
PremiumCompany AnnouncementsMirum Shareholders Approve Directors, Auditors and Compensation
1M ago
Mirum Therapeutics: Strong FOP Data and Priority Review Support Buy Rating and Unchanged $150 Price Target
Premium
Ratings
Mirum Therapeutics: Strong FOP Data and Priority Review Support Buy Rating and Unchanged $150 Price Target
1M ago
Buy Rating Reiterated on Mirum Pharmaceuticals as Zilurgisertib Data De-Risk Pipeline; $145 Price Target Unchanged with ~46% Upside Potential
Premium
Ratings
Buy Rating Reiterated on Mirum Pharmaceuticals as Zilurgisertib Data De-Risk Pipeline; $145 Price Target Unchanged with ~46% Upside Potential
1M ago
Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026
PremiumThe FlyIncyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026
2M ago
Mirum Expands Long-Term Safety Data for Livmarli in Rare Pediatric Liver Diseases
Premium
Company Announcements
Mirum Expands Long-Term Safety Data for Livmarli in Rare Pediatric Liver Diseases
2M ago
Mirum Pharmaceuticals initiated with a Buy at Citi
Premium
The Fly
Mirum Pharmaceuticals initiated with a Buy at Citi
2M ago
Mirum Pharmaceuticals Issues $690 Million Convertible Senior Notes
PremiumCompany AnnouncementsMirum Pharmaceuticals Issues $690 Million Convertible Senior Notes
2M ago
Mirum Pharmaceuticals announces $600M convertible senior notes offering
Premium
The Fly
Mirum Pharmaceuticals announces $600M convertible senior notes offering
3M ago
Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond James
Premium
The Fly
Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond James
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100